Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer | Synapse
July 15, 2025
Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Key Points
Main finding shows the combination of CDK2/4/6 inhibitor PF-06873600 and endocrine therapy is being tested for breast cancer.
A total of 151 patients were included in the safety analysis set to evaluate treatment effects and safety.
Demographics and baseline characteristics were carefully recorded to assess the population’s response to therapy.
These findings could lead to improved treatment options for breast cancer, contributing to advancements in cancer therapy.
Abstract
Demographics, baseline characteristics, and prior treatments—safety analysis set (N = 151).